10554-64-0

Basic information

• Product Name: 2-(2,3-DIHYDRO-1,4-BENZODIOXIN-6-YL)ETHANAMINE HYDROCHLORIDE
• Synonyms: 2-(2,3-dihydro-1,4-benzodioxin-6-yl)ethan-1-aMine;2-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)ethanaMine;2-(2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)ethanaMine hydrochloride
• CAS NO: 10554-64-0
• Molecular Formula: C₁₀H₁₃NO₂
• Molecular Weight: 179.22
• Mol File: 10554-64-0.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 295.7°Cat760mmHg
• Flash Point: 144.4°C
• Appearance: /
• Density: 1.157g/cm³
• Vapor Pressure: 0.0015mmHg at 25°C
• Refractive Index: 1.56
• CAS DataBase Reference: 2-(2,3-DIHYDRO-1,4-BENZODIOXIN-6-YL)ETHANAMINE HYDROCHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(2,3-DIHYDRO-1,4-BENZODIOXIN-6-YL)ETHANAMINE HYDROCHLORIDE(10554-64-0)
• EPA Substance Registry System: 2-(2,3-DIHYDRO-1,4-BENZODIOXIN-6-YL)ETHANAMINE HYDROCHLORIDE(10554-64-0)

Safety Data

• Hazardous Substances Data: 10554-64-0(Hazardous Substances Data)

Usage

General Description

2-(2,3-Dihydro-1,4-benzodioxin-6-yl)ethanamine hydrochloride, also known as 6-APDB, is a research chemical that belongs to the amphetamine class of compounds. It is a psychoactive substance with psychedelic and stimulant effects, and is used in scientific studies to investigate its potential therapeutic properties. 6-APDB acts as a selective serotonin releasing agent (SSRA), which means it increases the levels of serotonin in the brain, leading to mood enhancement and feelings of empathy. It is also known to produce hallucinogenic effects, making it popular in the underground recreational drug scene. However, due to its limited research and potential health risks, it is not approved for medical use and is considered a controlled substance in many countries.

InChI:InChI=1/C10H13NO2/c11-4-3-8-1-2-9-10(7-8)13-6-5-12-9/h1-2,7H,3-6,11H2

Upstream product

• 139-85-5 3,4-dihydroxybenzaldehyde 
• 10554-65-1 (E)-6-(2-nitrovinyl)-2,3-dihydro[1,4]benzodioxine 
• 29668-44-8 2,3-dihydro-benzo[1,4]dioxin-6-carbaldehyde 
• 14939-92-5 3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)propanoic acid 
• 17253-10-0 2-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)acetonitrile 
• 858789-85-2 3-(2,3-dihydro-benzo[1,4]dioxin-6-yl)-propionic acid amide 

Downstream Products

• 1233354-50-1 C₂₆H₂₇NO₈S 
• 1233354-63-6 C₂₆H₂₆FNO₈S 
• 1233354-89-6 C₂₅H₂₆FNO₆S 
• 380636-90-8 6-(3,4,5-trimethoxyphenyl)-2,3,6,7,8,9-hexahydro-[1,4]dioxino[2,3-g]isoquinoline 
• 380636-86-2 6-(3,4,5-trimethoxyphenyl)-2,3-dihyhydro[1,4]dioxino[2,3-g]isoquinoline 
• 1429118-96-6 C₂₇H₂₇NO₄ 
• 1429118-50-2 C₂₉H₃₁NO₇ 
• 1429118-67-1 C₂₉H₃₁NO₆ 
• 1429118-84-2 C₂₇H₂₉NO₅ 
• 854844-25-0 6-benzyl-2,3,8,9-tetrahydro-[1,4]dioxino[2,3-g]isoquinoline 

Relevant articles and documents

COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING NASH, NAFLD, AND OBESITY

The present technology relates to methods of treating NASH, NAFLD and/or obesity using compounds of Formulas I, II, III, IV, V, and/or VI. The methods include administering to a subject suffering from one or more of non-alcoholic steatohepatitis (NASH), non- alcoholic fatty liver disease (NAFLD) and/or obesity a therapeutically effective amount of such a compound

PYRIMIDINE DERIVATIVES AS PGE2 RECEPTOR MODULATORS

The present invention relates to pyrimidine derivatives of formula (I) wherein (R1)n, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description and their use in the treatment of cancer by modulating an immune response comprising a reactivation of the immune system in the tumor. The invention further relates to novel benzofurane and benzothiophene derivatives of formula (II) and their use as pharmaceuticals, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.

Compounds and Compositions for Modulating Lipid Levels and Methods of Preparing Same

The present technology relates to compounds of Formulas I-VI and methods of making and using such compounds. Methods of use include prevention and treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, hepatic steatosis, and metabolic syndrome. Compounds disclosed herein also increase HDL-C, lower total cholesterol, LDL-cholesterol, and triglycerides and increase hepatic LDL receptor expression, inhibit PCSK9 expression, and activate AMP-activated protein kinase.